Farinazzo Eleonora, Dianzani Caterina, Zalaudek Iris, Conforti Claudio, Grabbe Stephan, Goldust Mohamad
Dermatology Clinic, Maggiore Hospital, University of Trieste, Trieste, Italy.
Dermatology Section, Department of Plastic, Reconstructive and Cosmetic Surgery, Campus Biomedico University Hospital, Rome, Italy.
Clin Cosmet Investig Dermatol. 2021 Aug 6;14:991-997. doi: 10.2147/CCID.S325552. eCollection 2021.
The incidence of coronavirus disease 2019 (COVID-19)-related skin manifestations has progressively grown, in parallel with the global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreading. The available evidence indicates that cutaneous signs are heterogeneous and can be divided as follows: a) erythematous rashes, b) lesions of vascular origin, c) vesicular rashes, d) urticarial rashes, and e) acute generalized exanthematous pustulosis (AGEP), erythema multiforme (EM) and other polymorphic/atypical reactions. Most cutaneous manifestations appear simultaneously or after respiratory and/or systemic symptoms such as fever, even if rarely urticaria has been reported as the first sign of the disease. It has been proposed that erythematous and vesicular rashes, as well as urticaria, are the result of immunological activation against Sars-CoV-2, similarly to other viral exanthems; alternatively, reactivation or co-infection of herpesviruses and drug hypersensitivity represent possible etiologic diagnosis that has to be considered. Regarding lesions of vascular origin, ischemic ones are the result of systemic hypercoagulability established in severe infections, whereas chilblains seem to be linked to the type I-interferon massively produced to halt virus replication. AGEP is triggered by drugs, whereas EM could represent a delayed immune response to the virus or a hypersensitivity reaction to drugs elicited by the inflammatory process built to fight the infection. A further pathogenic hypothesis is that the virus, or its particles detected in the skin (particularly in endothelium and eccrine glands), could be responsible for certain skin reactions, including chilblains and EM. From the available data, it appears that chilblains are correlated with younger age and less severe disease, while ischemic manifestations occur in the elderly with severe infection. In conclusion, larger studies are needed to confirm the suggested pathogenetic mechanisms of COVID-19-related skin reactions and to determine the potential prognostic significance of each one.
随着全球严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的传播,2019冠状病毒病(COVID-19)相关皮肤表现的发生率逐渐上升。现有证据表明,皮肤症状具有异质性,可分为以下几类:a)红斑疹;b)血管源性病变;c)水疱疹;d)荨麻疹疹;e)急性泛发性脓疱性皮病(AGEP)、多形红斑(EM)和其他多形性/非典型反应。大多数皮肤表现与发热等呼吸道和/或全身症状同时出现或在其之后出现,尽管荨麻疹作为该疾病的首发症状报道较少。有人提出,红斑疹和水疱疹以及荨麻疹是针对Sars-CoV-2的免疫激活结果,类似于其他病毒疹;另外,疱疹病毒的再激活或合并感染以及药物超敏反应是必须考虑的可能病因诊断。关于血管源性病变,缺血性病变是严重感染时全身高凝状态的结果,而冻疮似乎与为阻止病毒复制而大量产生的I型干扰素有关。AGEP由药物引发,而EM可能代表对病毒的延迟免疫反应或对由对抗感染的炎症过程引发的药物的超敏反应。另一种致病假说认为,病毒或在皮肤中检测到的其颗粒(特别是在内皮和汗腺中)可能是某些皮肤反应的原因,包括冻疮和EM。从现有数据来看,冻疮与较年轻的年龄和较轻的疾病相关,而缺血性表现则发生在患有严重感染的老年人中。总之,需要更大规模的研究来证实COVID-19相关皮肤反应的推测发病机制,并确定每种反应的潜在预后意义。